June 14, 2016 Here are some additional posters on Pacritinib which were presented at ASCO 2016: PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF): OUTCOMES IN PATIENTS (PTS) WITH BASELINE (BL) THROMBOCYTOPENIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS AND RBC-TRANSFUSION DEPENDENCE IN THE PHASE III PERSIST-1 STUDY OF PACRITINIB VS. BEST AVAILABLE THERAPY PACRITINIB (PAC) VS… Read More »POSTERS RELATED TO PACRITINIB FROM ASCO 2016
June 8, 2016 Vice President Joe Biden addressed the American Society of Clincal Oncology meeting this year to discuss the Cancer Moonshot initiative. Watch the video here: http://am.asco.org/virtual-meeting-on-demand/presentation/biden-info Biden discusses the many unknowns about cancer, of which there are over 200 types, and how he needs oncologists and cancer researchers to band together to address this.… Read More »JOE BIDEN ADDRESSES ASCO ON THE CANCER MOONSHOT INITIATIVE
Although Pacritinib remains on full clinical hold, the FDA recently indicated to CTI BioPharma they would allow patients who were receiving benefit from Pacritinib treatment at the time the clinical hold was imposed to resume Pacritinib treatment under a Single Patient IND (SPI)/Compassionate Use program. In response, CTI BioPharma has developed a program that will… Read More »PACRITINIB REMAINS ON FULL CLINICAL HOLD BUT FDA OKS INDIVIDUAL INDS
A research project sponsored by Gilead is currently seeking participants for a study about experience with MPN symptoms. Do you experience symptoms of MPN? Are you 18 years old or older? Are you willing to be interviewed in person about your experience with MPN? If so, you may be eligible to participate in this study.… Read More »GILEAD SPONSORS NEW RESEARCH STUDY FOR MPN
This year’s American Society of Clinical Oncology meeting is not usually where much MPN-relevant science news gets posted. However, with quite a few ongoing clinical trials, including several in Phase 3, there are a few updates that people with PV, ET and MF should know about. We’ve compiled them below for your convenience: Researchers Yoojung… Read More »MPN UPDATES FROM ASCO 2016
March 11, 2016 Researchers from the University of Illinois at Chicago have just published a study that demonstrated a difference between Caucasians and non-Caucasians for those with myeloproliferative neoplasms. In an analyisis of data spanning over a decade, Dr. Rondelli et al found that Caucasian patients with PV and ET had a higher risk of progression… Read More »NEW RESEARCH OUT OF UIC SUGGESTS RACIAL DISPARITIES AMONG THOSE WITH MPN
February 19, 2016 Medicare has (somewhat) come through for people with Myelofibrosis by agreeing to provide coverage for those who qualify and are in need of a Stem Cell Transplant. After a process to petition them which included an initial ruling that would have put patients into randomized clinical trials, they have agreed to provide… Read More »MEDICARE APPROVES COVERAGE FOR SCT
February 10, 2016 The FDA has put the Phase 3 trials of Pacritinib on full clinical hold, noting overall survival results. CTI BioPharma Corp. has withdrawn their NDA (New Drug Application). Click here to read more. From their press release, CTI BioPharma states that they are working with the FDA to understand the issues and remains… Read More »UPDATE: PACRITINIB NOW ON FULL CLINICAL HOLD
January 28, 2016 Dr. Leonard Zon of Boston Children’s Hospital has made a discovery that shed light on the origins of cancer. Using zebrafish, Dr. Zon discovered a melanoma cell that had reverted to an embryonic form, when it could have developed into any cell type. As it began to divide, cancer genes took over… Read More »ZEBRAFISH SHINES LIGHT ON MELANOMA AND PROVIDES HOPE FOR MPN
December 11, 2015 In the journal Blood, Jean-Jacques Kiladjian and colleagues reported their findings that Pegylated interferon alpha induces hematological and molecular remission in CALR mutated essential thrombocythemia patients. 31 ET patients were followed in the course of this study. The CALR mutant allele burden was reduced from 41% to 26% following treatment, with two… Read More »2015 BLOOD JOURNAL REPORTS THAT CALR MUTATION REDUCED WITH PEGASYS
